Journal of Clinical Epidemiology
Volume 63, Issue 4 , Pages 407-411 , April 2010

Outpatient urticaria diagnosis codes have limited predictive value for same-day influenza vaccine adverse event detection

  • Kristen M. Moore

      Affiliations

    • Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care, Boston, MA, USA
    • ,
  • April Duddy

      Affiliations

    • Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care, Boston, MA, USA
    • ,
  • Grace M. Lee

      Affiliations

    • Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care, Boston, MA, USA
    • ,
  • Priscilla Velentgas

      Affiliations

    • Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care, Boston, MA, USA
    • ,
  • Dale R. Burwen

      Affiliations

    • Division of Epidemiology, Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD, USA
    • ,
  • Richard Platt

      Affiliations

    • Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care, Boston, MA, USA
    • ,
  • Jeffrey S. Brown

      Affiliations

    • Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care, Boston, MA, USA
    • Corresponding Author InformationCorresponding author. Tel.: +617-509-9986; fax: +617-859-8112.

,Accepted 6 August 2009.

References 

  1. Centers for Disease Control and Prevention . Update: novel influenza A (H1N1) virus infections—worldwide, May 6, 2009. MMWR Morb Mortal Wkly Rep. 2009;58:453–458
  2. Centers for Disease Control and Prevention . Serum cross-reactive antibody response to a novel Influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep. 2009;58:521–524
  3. Birnbaum HG, Cremieux PY, Greenberg PE, LeLorier J, Ostrander JA, Venditti L. Using healthcare claims data for outcomes research and pharmacoeconomic analyses. Pharmacoeconomics. 1999;16:1–8
  4. Zingmond DS, Wilber KH, Maclean CH, Wenger NS. Measuring the quality of care provided to community dwelling vulnerable elders dually enrolled in Medicare and Medicaid. Med Care. 2007;45:931–938
  5. Platt R, Davis R, Finkelstein J, Go AS, Gurwitz JH, Roblin D, et al. Multicenter epidemiologic and health services research on therapeutics in the HMO Research Network Center for Education and Research on Therapeutics. Pharmacoepidemiol Drug Saf. 2001;10:373–377
  6. Udvarhelyi IS, Gatsonis C, Epstein AM, Pashos CL, Newhouse JP, McNeil BJ. Acute myocardial infarction in the Medicare population: process of care and clinical outcomes. JAMA. 1992;268:2530–2536
  7. Collins AJ, Chen SC, Gilbertson DT, Foley RN. CKD surveillance using administrative data: impact on the health care system. Am J Kidney Dis. 2009;53(3 suppl 3):S27–S36
  8. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58:323–337
  9. Brown JS, Kulldorff M, Chan KA, Davis RL, Graham D, Pettus PT, et al. Early detection of adverse drug events within population-based health networks: application of sequential testing methods. Pharmacoepidemiol Drug Saf. 2007;16:1275–1284
  10. Davis RL, Kolczak M, Lewis E, Nordin J, Goodman M, Shay DK, et al. Active surveillance of vaccine safety: a system to detect early signs of adverse events. Epidemiology. 2005;16:336–341
  11. Lieu TA, Kulldorff M, Davis RL, Lewis EM, Weintraub E, Yih K, et al. Real-time vaccine safety surveillance for the early detection of adverse events. Med Care. 2007;45(10 suppl 2):S89–S95
  12. Burwen DR, LaVoie L, Braun MM, Houck P, Ball R. Evaluating adverse events after vaccination in the Medicare population. Pharmacoepidemiol Drug Saf. 2007;16:753–761
  13. Greene SK, Yin R, Kulldorff M, Lieu TA, Lewis EM, McClure DL, et al. Influenza vaccine safety: simulating real-time surveillance for adverse events in the Vaccine Safety Datalink project. Paper presented at: 48th Annual ICAAC/46th Annual IDSA Conference. Washington, DC. October 25, 2008.
  14. Brown JS, Moore KM, Braun MM, Ziyadeh N, Chan KA, Lee GM, et al. Active influenza vaccine safety surveillance: potential within a healthcare claims environment. Med Care 2009 [ePub ahead of press].
  15. Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA. 1999;281:824–829
  16. Varricchio F, Iskander J, Destefano F, Ball R, Pless R, Braun MM, et al. Understanding vaccine safety information from VAERS. Pediatr Infect Dis J. 2004;23:287–294
  17. Centers for Disease Control and Prevention . Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Morb Mortal Wkly Rep. 2008;57(RR07):1–60
  18. Hambidge SJ, Glanz JM, France EK, McClure D, Xu S, Yamasaki K, et al. Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old. JAMA. 2006;296:1990–1997
  19. France EK, Glanz JM, Xu S, Davis RL, Black SB, Shinefield HR, et al. Safety of the trivalent inactivated influenza vaccine among children: a population-based study. Arch Pediatr Adolesc Med. 2004;158:1031–1036
  20. Tata LJ, West J, Harrison T, Farrington P, Smith C, Hubbard R. Does influenza vaccination increase consultations, corticosteroid prescriptions, or exacerbations in subjects with asthma or chronic obstructive pulmonary disease?. Thorax. 2003;58:835–839
  21. Moore K, Brown JS for the HMO Research Network Center for Education and Research in Therapeutics. Variation in ICD-9 diagnosis coding of potential adverse events. 25th International Conference on Pharmacoepidemiology and Therapeutics Risk Management. August 2009; Providence, RI.

PII: S0895-4356(09)00236-4

doi: 10.1016/j.jclinepi.2009.08.002

Journal of Clinical Epidemiology
Volume 63, Issue 4 , Pages 407-411 , April 2010

Article Tools

* Image Usage & Resolution